Search the Newsroom
Filter By
News Type
Showing 31 - 40 of 69 results
International Research Team Develops Consensus Variant Classification Guidelines for Genomic Variants in Mitochondrial DNA
Improved and standardized variant curation guidelines will improve diagnostic accuracy for patients with mitochondrial disease evaluation.
First-of-its-Kind, All-in-One Resource for Genetics of Mitochondrial Disease Released
CHOP’S Mitochondrial Medicine team helped bring this book for researchers and clinicians to life.
AML Immunotherapy Trial Opens
CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.
CHOP Researchers Discover New, Aggressive Form of Mitochondrial Disease
CHOP Researchers Discover New, Aggressive Form of Mitochondrial Disease.
Genetic Testing 101: What Parents Need to Know
If your child has symptoms of an inherited condition or one that might be caused by a spontaneous gene mutation, your doctor may recommend genetic testing. Here's what you need to know.
Existing Drug May Have Potential to Treat Mitochondrial Disease
New results in cell and animal studies suggest that a drug already used for a rare kidney disease could benefit patients with mitochondrial disorders.
The Case for Performing Percutaneous Muscle Biopsy
Dr. Cunningham writes about when and why should a muscle biopsy be considered in the evaluation of mitochondrial disease, and how to obtain a muscle biopsy.
Sideroblastic Anemia Is a Red-flag Sign of Single Large-scale Mitochondrial DNA Deletion Syndrome
Using the case of a 24-month-old African-American boy, Drs. Ganetzky and Goldstein discuss sideroblastic anemia and how it might be an indicator for multisystem mitochondrial disease.
Immunotherapy: What’s Next for CAR-T Therapy
Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.
Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient
An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.